[1]
|
中华人民共和国国家卫生健康委员会. 原发性肝癌诊疗指南(2022年版) [J]. 肿瘤综合治疗电子杂志, 2022, 8(2): 16-53.
|
[2]
|
曹毛毛, 李贺, 孙殿钦, 等. 全球肝癌2020年流行病学现状[J]. 中华肿瘤防治杂志, 2022, 29(5): 322-328.
|
[3]
|
邓国瑜, 陈洁, 黄山, 等. 基于巴塞罗那分期与香港分期肝细胞肝癌患者不同治疗方案生存率的比较[J]. 肿瘤防治研究, 2019,46(4): 327-332.
|
[4]
|
Ganesan, P. and Kulik, L.M. (2023) Hepatocellular Carcinoma: New Developments. Clinics in Liver Disease, 27, 85- 102. https://doi.org/10.1016/j.cld.2022.08.004
|
[5]
|
Vogel, A., Meyer, T., Sapisochin, G., et al. (2022) Hepatocellular Carcinoma. Lancet, 400, 1345-1362.
https://doi.org/10.1016/S0140-6736(22)01200-4
|
[6]
|
孙惠川, 谢青, 荚卫东, 等. 肝癌转化治疗中国专家共识(2021版) [J]. 中国实用外科杂志, 2021, 41(6): 618-632.
|
[7]
|
Mazzaferro, V., Sposito, C., Bhoori, S., et al. (2013) Yttrium-90 Radioembolization for Intermediate-Advanced Hepatocellular Carcinoma: A Phase 2 Study. Hepatology, 57, 1826-1837. https://doi.org/10.1002/hep.26014
|
[8]
|
Saini, A., Wallace, A., Alzubaidi, S., et al. (2019) History and Evolution of Yttrium-90 Radioembolization for Hepatocellular Carcinoma. Journal of Clinical Medicine, 8, 55. https://doi.org/10.3390/jcm8010055
|
[9]
|
牛惠敏, 王志恒, 高石鑫, 等. 钇90放射性微球在肝脏恶性肿瘤中的应用及进展[J]. 肝癌电子杂志, 2021, 8(4): 36- 40.
|
[10]
|
Reig, M., Forner, A., Rimola, J., et al. (2022) BCLC Strategy for Prognosis Prediction and Treatment Recommendation: The 2022 Update. Journal of Hepatology, 76, 681-693. https://doi.org/10.1016/j.jhep.2021.11.018
|
[11]
|
Biederman, D.M., Titano, J.J., Bishay, V.L., et al. (2017) Radiation Segmentectomy versus TACE Combined with Microwave Ablation for Unresectable Solitary Hepatocellular Carcinoma Up to 3 cm: A Propensity Score Matching Study. Radiology, 283, 895-905. https://doi.org/10.1148/radiol.2016160718
|
[12]
|
Dhondt, E., Lambert, B., Hermie, L., et al. (2022) 90Y Radioembo-lization versus Drug-Eluting Bead Chemoembolization for Unresectable Hepatocellular Carcinoma: Results from the TRACE Phase II Randomized Controlled Trial. Radiology, 303, 699-710. https://doi.org/10.1148/radiol.211806
|
[13]
|
刘允怡. 树脂钇90微球在肝外科治疗肝细胞癌的应用[J]. 中国普外基础与临床杂志, 2022, 29(9): 1124-1128.
|
[14]
|
宋莉, 邹英华. 钇90微球管理专家共识[J]. 中国介入影像与治疗学, 2021, 18(6): 321-325.
|
[15]
|
Kolligs, F., Arnold, D., Golfieri, R., et al. (2023) Factors Impacting Survival after Transarterial Radioembolization in Patients with Hepato-cellular Carcinoma: Results from the Prospective CIRT Study. JHEP Reports, 5, 100633.
https://doi.org/10.1016/j.jhepr.2022.100633
|
[16]
|
Levillain, H., Bagni, O., Deroose, C.M., et al. (2021) International Recommendations for Personalised Selective Internal Radiation Therapy of Primary and Metastatic Liver Diseases with Yttrium-90 Resin Microspheres. European Journal of Nuclear Medicine and Molecular Imaging, 48, 1570-1584. https://doi.org/10.1007/s00259-020-05163-5
|
[17]
|
Coldwell, D., Sangro, B., Wasan, H., et al. (2011) General Se-lection Criteria of Patients for Radioembolization of Liver Tumors: An International Working Group Report. American Journal of Clinical Oncology, 34, 337-341.
https://doi.org/10.1097/COC.0b013e3181ec61bb
|
[18]
|
Liu, D.M., Leung T.W., Chow, P.K., et al. (2022) Clinical Consensus Statement: Selective Internal Radiation Therapy with Yttrium 90 Resin Microspheres for Hepatocellular Car-cinoma in Asia. International Journal of Surgery, 102, 106094. https://doi.org/10.1016/j.ijsu.2021.106094
|
[19]
|
Kim, S.P., Cohalan, C., Kopek, N., et al. (2019) A Guide to 90Y Radioembolization and Its Dosimetry. Physica Medica, 68, 132-145. https://doi.org/10.1016/j.ejmp.2019.09.236
|
[20]
|
Miller, F.H., Lopes, V.C., Gabr, A., et al. (2021) Evolution of Ra-dioembolization in Treatment of Hepatocellular Carcinoma: A Pictorial Review. Radiographics, 41, 1802-1818. https://doi.org/10.1148/rg.2021210014
|
[21]
|
Gabr, A., Kulik, L., Mouli, S., et al. (2021) Liver Transplantation Fol-lowing Yttrium-90 Radioembolization: 15-Year Experience in 207-Patient Cohort. Hepatology, 73, 998-1010. https://doi.org/10.1002/hep.31318
|
[22]
|
Salem, R., Gordon, A.C., Mouli, S., et al. (2016) Y90 Radioembolization Significantly Prolongs Time to Progression Compared with Chemoembolization in Patients with Hepatocellular Carcino-ma. Gastroenterology, 151, 1155-1163.
https://doi.org/10.1053/j.gastro.2016.08.029
|
[23]
|
Ponziani, F.R., Santopaolo, F., Posa, A., et al. (2022) SIRT in 2025. CardioVascular and Interventional Radiology, 45, 1622-1633. https://doi.org/10.1007/s00270-022-03228-6
|
[24]
|
Chakravarty, R., Dash, A. and Pillai, M.R. (2012) Availability of Yttrium-90 from Strontium-90: A Nuclear Medicine Perspective. Cancer Biotherapy and Radiopharmaceuticals, 27, 621-641. https://doi.org/10.1089/cbr.2012.1285
|